Niraparib (Zejula)

Ingredients: Niraparib
Dosage Form: Capsules
Innovator’s Brand Name: Zejula
Generic Brand Name: Paribac
Generic Manufacturer: Ziska Pharma

Indications:
Niraparib is indicated as maintenance monotherapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum‑based chemotherapy.

Dosage and Administration:
The recommended dose is 300 mg orally once daily; if a dose is missed, skip it without taking an extra dose; adjust the dose based on tolerability.

Adverse Reactions:
Common adverse reactions include nausea, thrombocytopenia, fatigue, anemia, constipation, vomiting, abdominal pain, neutropenia, insomnia, headache, and upper respiratory tract infection; serious reactions primarily include thrombocytopenia and anemia.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link